Summit Therapeu ADR (SMMT) 10.02 $SMMT Summit Receives

New Post Public Reply Private Reply Replies (0) Message Board

Sep 27, 2016 at 5:29 AM

Summit Therapeu ADR (SMMT) 10.02 $SMMT

Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire - Mon Sep 26, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today announces it has received Fast Track designation from the US Food and Drug Administration ('FDA'

for ezutromid in the treatment of DMD. Ezutromid is a utrophin modulator and represents a potential disease modifying treatment for all patients with the fatal muscle wasting disease DMD.
SMMT: 10.02 (+1.29)

Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
GlobeNewswire - Mon Sep 12, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today launches www.utrophintrials.com as an online resource for the DMD community. This website is dedicated to providing up to date information on utrophin and Summit's utrophin modulator clinical trials.
SMMT: 10.02 (+1.29)

Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress
GlobeNewswire - Thu Sep 08, 6:00AM CDT
-- Conference call to be held 1:00pm BST / 8:00am EDT
SMMT: 10.02 (+1.29)

Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Wed Sep 07, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual Rodman & Renshaw Global Investment Conference, 13 September 2016 at 2:35pm EDT in New York City.
SMMT: 10.02 (+1.29)

Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016
GlobeNewswire - Mon Sep 05, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016.
SMMT: 10.02 (+1.29)

Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
GlobeNewswire - Tue Aug 09, 6:01AM CDT
-- New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patients
SMMT: 10.02 (+1.29)

Summit Therapeutics to Present at Canaccord Genuity Growth Conference
GlobeNewswire - Fri Aug 05, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Erik Ostrowski, Chief Financial Officer, will present at the Canaccord Genuity Growth Conference, 11 August 2016 at 1:30pm EDT in Boston.
SMMT: 10.02 (+1.29)

First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today announces that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid (formerly SMT C1100) in patients with DMD. Ezutromid dosing is expected to follow a screening period of up to 28 days.
SMMT: 10.02 (+1.29)

Summit Therapeutics to Host Utrophin R&D Day 15 June 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit's management on 15 June 2016 in New York City.
SMMT: 10.02 (+1.29)

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the first quarter ended 30 April 2016.
SMMT: 10.02 (+1.29)

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
GlobeNewswire - Tue May 31, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016.
SMMT: 10.02 (+1.29)

Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
GlobeNewswire - Mon May 23, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole's preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.
SMMT: 10.02 (+1.29)

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Tue May 10, 6:07AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the fourth quarter and fiscal year ended 31 January 2016.
SMMT: 10.02 (+1.29)

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Fri May 06, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2016 on Tuesday, 10 May 2015.
SMMT: 10.02 (+1.29)

Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection ('CDI'

, announces the strengthening of the intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States Patent and Trademark Office.
SMMT: 10.02 (+1.29)

Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
GlobeNewswire - Tue Apr 26, 6:02AM CDT
-- Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
SMMT: 10.02 (+1.29)

Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
SMMT: 10.02 (+1.29)

Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
GlobeNewswire - Thu Jan 21, 6:11AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally administered, small molecule utrophin modulator that the Company believes has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. Utrophin is functionally and structurally similar to dystrophin, a protein which is essential for the healthy function of muscles.
SMMT: 10.02 (+1.29)

Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
GlobeNewswire - Tue Jan 19, 6:16AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces that the European Patent Office ('EPO'

has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent having faced no challenge. The patent covers the use of ridinilazole for the treatment of infections caused by the bacterium Clostridium difficile.
SMMT: 10.02 (+1.29)

Summit Corporate Services secures multi-year service agreement with Dhama USA
PRWeb - Tue Dec 29, 7:31AM CST
Summit Corporate Services, Inc. a global outsourcing and 3rd Party Logistics solutions provider (3PL) serving the life science, medical device and consumer industries announced today that it is expanding its presence in the ecommerce/retail market by signing a multi-year outsourcing service agreement with dhamaUSA. Under this new agreement Summit will deliver a comprehensive range of retail services including: customer service, technical and product support, inventory management, warehousing, distribution, multi-channel order processing and fulfillment, invoicing, payment processing, as well as ERP hosting and financial reporting.
SMMT: 10.02 (+1.29)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Soluna Schedules Q3 2026 Earnings Call: What To Expect

Soluna's Upcoming Earnings Call: A Crucial Update Here we are again, folks—floating on the edge of another one of Soluna Holdings' earnings calls. Mark November 16, 2026, on your calendar because that's when Soluna's slated to drop its third quarter financials and walk us through the numbers. At 5:00 PM Eastern Time, they're firing up the webcast and phone lines for a...

Skyways Unleashes Skyreach: A Bold Step in Autonomous Cargo

Dropping Cargo the New Way No more messing around with runways and cumbersome logistics—Skyways just took a sledgehammer to traditional cargo transport with the launch of its Skyreach platform. This bad boy is a long-range autonomous Vertical Takeoff and Landing (VTOL) aircraft that promises to shake up the defense and commercial sectors. We've got flights kicking off...

Unquiet Nights' New Tune Echoes Rome's Eternal Lingering

Irish Rockers Unquiet Nights Celebrate a Poignant Release Ever heard of a band that takes its darn sweet time? Well, Unquiet Nights just dropped a single after sitting on it for a solid 15 years. 'Last Days of Rome' isn’t just a new tune; it’s a love letter to both music and the eternal echoes of Rome’s history. These Belfast rockers have been crafting this piece...

Xinjiang Women Embrace New Horizons in Tianshan Peaks

Scaling New Heights in Xinjiang Up there on the Tianshan Mountains, looking past those towering cliffs, what catches the eye isn't just breathtaking views but rising opportunities. In the land of Xinjiang, far from the bustling metropolises, young women are finding platforms to not just exist but to thrive. City by city, the narrative is changing as these women carve...

Invitation Homes Supports Veterans in Skilled Trades Push

A New Chapter for Veterans in the Workforce Normally when a company kicks off a partnership, it’s all about fluff and show. But this thing with Invitation Homes and the Home Builders Institute (HBI) is the real deal for veterans looking to switch gears into new careers. The objective is simple—get transitioning service members, veterans, and their families rolling...

Innovative Breaker Bar Reinvents Torque Application

A Fresh Take for Do-It-Yourselfers Ever tried to budge a stubborn bolt and felt like you were arm wrestling a gorilla? This is why a Winter Garden, Florida inventor has stepped up to the plate with the "BREAK IT," an adjustable breaker bar that promises to make this grimy task much smoother. Forget the days of waving around a cumbersome cheater bar. With this gadget,...

Envision and ju:niz Boost Germany's Energy Storage

Germany Charges Ahead with Renewable Energy Storage Germany's on a mission, folks, and it's all about beefing up their renewable energy infrastructure. Out in Bavaria, Envision Energy and ju:niz Energy are prepping a significant leap forward. They're rolling out a big undertaking—a 442 MWh battery energy storage system (BESS) with their Smareg 13 project in Vöhringen....

Strathcona and Greenfire Set Sights on Major Merger

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

AI Shopping Surge: WeFetch.ai's Bold Rebrand Move

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Hyperscale Data Plans Major Stock Exchange Deal

Hyperscale's Bold Move: Exchange Offer Hits the Market Man, when a company believes its market value is out of whack, you get moves like this. Hyperscale Data, strutting under ticker symbol NYSE:GPUS, is swinging for the fences with an exchange offer, aiming to mop up $50 million worth of its common stock with a sweet deal that’s sure to grab any investor's attention....